Neumora Therapeutics, Inc. (NMRA)

Neumora Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	116.83	182.53	142.15	374.04	240.94	409.25
Short-Term Investments	-	-	165.43	79.94	130.94	-
Cash & Short-Term Investments	116.83	182.53	307.58	453.98	371.88	409.25
Cash Growth	-46.30%	-40.66%	-32.25%	22.08%	-9.13%	113.17%
Other Receivables	-	-	-	-	0.92	0.2
Receivables	-	-	-	-	0.92	0.2
Prepaid Expenses	8.04	8.01	5.26	18	1.62	1.2
Restricted Cash	-	-	1.21	-	0.05	0.13
Other Current Assets	-	-	-	6.3	13.48	4.84
Total Current Assets	124.87	190.54	314.06	478.28	387.96	415.6
Property, Plant & Equipment	0.32	0.46	2.92	6.86	10.64	4.04
Long-Term Investments	-	-	-	9.85	23.51	-
Long-Term Deferred Charges	-	-	-	-	2.9	1.83
Other Long-Term Assets	0.05	0.05	-	1.21	1.23	7.82
Total Assets	125.25	191.05	316.97	496.2	426.23	429.3

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	4.15	3.38	3.31	0.34	7.15	1.64
Accrued Expenses	20.26	28.79	24.59	21.26	11.54	19.1
Current Portion of Leases	0.3	0.28	1.85	3.38	3.37	1.06
Other Current Liabilities	-	-	0.13	0.14	1.64	1.49
Total Current Liabilities	27.78	32.45	29.89	25.11	23.7	23.28
Long-Term Debt	52.91	54.53	-	-	-	-
Long-Term Leases	0.04	0.19	-	1.85	5.07	1
Other Long-Term Liabilities	-	-	0.02	0.16	0.63	0.39
Total Liabilities	80.73	87.18	29.91	27.12	29.4	24.66

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.02	0.02	0.02	0.02	0	0.01
Additional Paid-In Capital	1,325	1,288	1,234	1,173	21.43	11.37
Retained Earnings	-1,281	-1,184	-947.22	-703.43	-467.51	-336.61
Comprehensive Income & Other	-	-	0.06	-0.08	-0.77	-
Total Common Equity	44.52	103.87	287.06	469.08	-446.85	-325.22
Shareholders' Equity	44.52	103.87	287.06	469.08	396.84	404.64
Total Liabilities & Equity	125.25	191.05	316.97	496.2	426.23	429.3

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	53.25	55.01	1.85	5.23	8.44	2.05
Net Cash (Debt)	63.58	127.52	305.73	458.6	386.95	407.2
Net Cash Growth	-67.83%	-58.29%	-33.34%	18.52%	-4.97%	114.39%
Net Cash Per Share	0.37	0.78	1.92	7.05	14.22	18.60
Filing Date Shares Outstanding	187.9	182.04	161.98	158.89	32.61	31.98
Total Common Shares Outstanding	186.85	174.26	161.71	158.83	32.61	31.98
Working Capital	97.1	158.09	284.17	453.17	364.26	392.33
Book Value Per Share	0.24	0.60	1.78	2.95	-13.70	-10.17
Tangible Book Value	44.52	103.87	287.06	469.08	-446.85	-325.22
Tangible Book Value Per Share	0.24	0.60	1.78	2.95	-13.70	-10.17
Machinery	-	0.23	3.19	3.18	2.94	2.3
Construction In Progress	-	-	-	0.04	0.51	0.22
Leasehold Improvements	-	-	-	-	0.02	0.26

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Aug 14, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 20, 2026

Data Sources Report a data error